Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy

J Asthma. 2020 Jan;57(1):79-81. doi: 10.1080/02770903.2018.1545857. Epub 2019 Mar 1.

Authors

Dan Yang¹, Tingxuan Huang¹, Bicui Liu^{1

2}, Zhuman Du¹, Chuntao Liu¹

Affiliations

¹ West China School of Medicine and West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Affiliated Minda Hospital of Hubei Institute for Nationalities, Enshi, Hubei, China.

PMID: 30821528
DOI: 10.1080/02770903.2018.1545857

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / blood
Asthma / diagnosis
Asthma / drug therapy*
Asthma / immunology
Biomarkers / analysis
Biomarkers / metabolism
Chemokine CCL17 / analysis
Chemokine CCL17 / metabolism
Chemokine CCL26 / analysis
Chemokine CCL26 / metabolism
Eosinophils / immunology
Exhalation
Humans
Leukocyte Count
Nitric Oxide / analysis
Randomized Controlled Trials as Topic*
Th2 Cells / immunology
Th2 Cells / metabolism*
Treatment Outcome

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Biomarkers
CCL17 protein, human
CCL26 protein, human
Chemokine CCL17
Chemokine CCL26
Nitric Oxide
dupilumab